IFNA1 and viral infectious disease: Despite this refractoriness signature on AP-1-targeted loci, the AS03 adjuvant led to elevated antiviral vigilance pronounced by enhanced IRF accessibility, IFN production, and protection against heterogeneous viral infection [44].